Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1706 studies found for:    HER2
Show Display Options
Rank Status Study
1 Recruiting HER2-Peptide Vaccination of Patients With Solid Tumors
Conditions: Gastric Cancer;   Breast Cancer
Interventions: Drug: Cyclophosphamide;   Drug: Sargramostim;   Drug: HER2-Peptid-Vakzine;   Drug: Imiquimod
2 Active, not recruiting Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy
Condition: HER2 Positive Malignancies
Intervention: Genetic: TGFBeta resistant HER2/EBV-CTLs
3 Recruiting A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer
Conditions: Breast Cancer;   Ovarian Cancer;   Lung Cancer;   Gastric Cancer;   Colorectal Cancer;   Glioma;   Pancreatic Cancer
Intervention: Biological: Anti-HER2 CAR-T
4 Unknown  HER2 Positive CTC in Advanced Gastric Cancer
Condition: HER2 Positive Advanced Gastric Cancer
Intervention: Device: Cell Search® CTC epithelial kit
5 Active, not recruiting Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Biological: sargramostim;   Drug: rintatolimod;   Other: laboratory biomarker analysis
6 Withdrawn Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Drug: cyclophosphamide;   Biological: ex vivo-expanded HER2-specific T cells;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Other: immunoenzyme technique
7 Recruiting T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma
Condition: Glioblastoma
Intervention: Genetic: HER2-specific T cells
8 Recruiting Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma
Condition: Sarcoma
Interventions: Genetic: Autologous HER2-specific T cells;   Drug: Fludarabine;   Drug: Cyclophosphamide
9 Unknown  HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025
Condition: HER2-positive Breast Cancer
Intervention: Other: Radiolabeled [68Ga]ABY-025
10 Recruiting Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing
Conditions: Breast Neoplasms;   Breast Cancer;   Adenocarcinomas;   Metastatic Solid Tumors Characterized by HER2/Neu Expression
Intervention: Biological: Autologous Ad HER2 dendritic cell vaccine
11 Suspended Vaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy
Conditions: HER2/Neu Positive;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu Intracellular Domain Protein;   Other: Laboratory Biomarker Analysis;   Biological: Pertuzumab;   Other: Placebo;   Biological: Polysaccharide-K;   Biological: Trastuzumab
12 Recruiting Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors
Conditions: Advanced HER-2 Positive Solid Tumors;   Chemotherapy Refactory;   HER-2 Antibody Inhibitor Therapy Refactory
Intervention: Biological: CART-HER-2
13 Recruiting Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
Conditions: Breast Cancer;   HER2-negative Breast Cancer;   HER2-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: Carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Drug: bevacizumab;   Drug: trastuzumab;   Procedure: magnetic resonance imaging;   Procedure: therapeutic conventional surgery
14 Enrolling by invitation Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab
Conditions: HER2/Neu Positive;   HLA-A2 Positive Cells Present;   Stage IV Breast Cancer;   Stage IV Ovarian Cancer
Interventions: Biological: HER-2/neu Peptide Vaccine;   Other: Laboratory Biomarker Analysis
15 Unknown  Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Biological: HER-2/neu peptide vaccine;   Other: laboratory biomarker analysis
16 Active, not recruiting Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: HER-2/neu intracellular domain protein;   Procedure: leukapheresis;   Other: laboratory biomarker analysis;   Biological: sargramostim;   Other: immunologic technique;   Biological: synthetic tumor-associated peptide vaccine therapy
17 Recruiting Palbociclib in Treating Patients With Metastatic HER-2 Positive or Triple-Negative Breast Cancer With Brain Metastasis
Conditions: Breast Carcinoma Metastatic in the Brain;   Estrogen Receptor Negative;   HER2/Neu Negative;   HER2/Neu Positive;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Procedure: Cognitive Assessment;   Drug: Palbociclib;   Procedure: Quality-of-Life Assessment;   Biological: Trastuzumab
18 Completed Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
Conditions: HER2-positive Breast Cancer;   Recurrent Breast Cancer;   Recurrent Non-small Cell Lung Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Stage IV Breast Cancer;   Stage IV Non-small Cell Lung Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Ovarian Germ Cell Tumor
Interventions: Drug: ex vivo-expanded HER2-specific T cells;   Drug: cyclophosphamide;   Biological: denileukin diftitox;   Other: flow cytometry;   Other: immunoenzyme technique
19 Completed Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients
Conditions: Breast Neoplasms;   Secondary;   HER2 Positive Carcinoma of Breast
Intervention: Drug: Zr89-trastuzumab
20 Completed
Has Results
Trastuzumab, Ixabepilone, and Carboplatin in Treating Patients With HER2/Neu-Positive Metastatic Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Biological: trastuzumab;   Drug: ixabepilone;   Drug: carboplatin;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years